Editas Medicine
300 Third Street, First Floor
Cambridge
Massachusetts
02142
United States
Tel: 617-401-9000
Website: http://editasmedicine.com/
Email: dan@purecommunicationsinc.com
About Editas Medicine
Editas Medicine is a transformative genome editing company founded by world leaders in the fields of genome editing, protein engineering, and molecular and structural biology, with specific expertise in CRISPR/Cas9 and TALENs technologies.
The company's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.
Editas was founded in 2013 with $43 million in Series A venture capital financing led by leading health care venture capital firms Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.
YEAR FOUNDED:
2013
LEADERSHIP:
Founders: Feng Zhang, Jennifer Doudna, George Church, J. Keith Joung, and David Liu
CEO: Karine Bosley
CFO: Andrew Hack
COO: Alexandra Glucksmann
CTO: Vic Myer
JOBS:
Please click here for Editas Medicine job opportunities.
FOLLOW EDITAS MEDICINE:
Tweets by Editas Medicine
Currently, there are no jobs for this employer on BioSpace.
Browse jobs with BioSpace Featured Employers here.